Yep and the length of the trials does not mean a transaction(s) are not on the cards earlier. The main focus is EMD AML approval under 505(b)(2) pathway from the P2 trials. Then Zantrene may be used off-label for other indications even if trial are not completed.
This was a very interesting announcement today, lots of detail, questions and observations. Will need to let it all sink in for a couple of days - but overall positive that there is a response to Melanoma where PD-1 failed. The main question is whether this indication is commercial viable (over say ccRCC), think it may be subject to more data and input from key opinion leaders.
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-55
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |